How a First-of-its-Kind “Microglia Map” from Recursion and Roche and ...
Oct 29, 2025 · A first-of-its-kind whole genome map from researchers at Recursion with partners Roche and Genentech offers a new approach to exploring novel targets and pathways for a wide range of …
Recursion Reports Second Quarter 2025 Financial Results and Provides ...
Jun 30, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, …
Recursion Pharmaceuticals, Inc.
Recursion Pharmaceuticals, Inc.
Recursion Reports Third Quarter 2025 Financial Results and Provides ...
Oct 9, 2025 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Montréal, New York, London, …
Our Unique Approach to AI Drug Discovery | Recursion
Unlike traditional drug discovery, which begins with a specific target or hypothesis, we leverage the Recursion OS — our drug discovery and development platform for AI in pharma connects technical …
Pioneering AI Drug Discovery | Recursion
All of our results feed back into our drug discovery and drug development platform – the Recursion Operating System – in a continuously improving feedback loop.
Recursion Pharmaceuticals, Inc. - MIT and Recursion Release Boltz-2 ...
Jun 6, 2025 · Powered by Recursion's NVIDIA supercomputer for its training and validation, this next-generation AI model achieves best-in-class accuracy in jointly modeling complex structures and …
Recursion Pharmaceuticals, Inc. - Recursion and Exscientia Enter ...
Aug 8, 2024 · Recursion is headquartered in Salt Lake City, where it is a founding member of BioHive, the Utah life sciences industry collective. Recursion also has offices in Toronto, Montreal, the San …
Recursion's Drug Discovery Pipeline | Recursion
Leveraging the power of the Recursion OS, we are building an industry-leading pipeline of potential best-in-class and first-in-class therapeutic assets. We focus on indications with high unmet need, …
LOWE - Recursion
Within Recursion, this process typically requires biologists to delineate biological pathways and establish novel map relationships, followed by chemists optimizing chemical series for the selected targets.